Valsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs), which exhibit the ability to selectively obstruct the angiotensin receptor type 1 (AR1R), hence deterring the effects of angiotensin II on the blood vessels, and consequently regulating the blood pressure. It is noteworthy that Valsartan is primarily intended to treat hypertension, heart failure, and myocardial infarction, with its debut approval by the FDA dating back to December 1996, all thanks to the efforts of Novartis in developing it. Valsartan has become widely recognized and hailed as a vital drug in the management of cardiovascular diseases, which serves as a testament to its efficacy and utility. Click on the image below to begin the exploration journey of Valsartan through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!